Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
CONCLUSION: LMWH+LDA+PRAV increased serum NO levels and significantly improved placental haemodynamics and maternal and neonatal outcomes in women and mice with OAPS. A role for eNOS/NO in mediating the placental vasculoprotective effects in OAPS-mice was demonstrated, strengthening the concept that impaired NO production is a crucial mediator in the pathogenesis of OAPS and a potential target for pharmacological interventions. The efficacy of pravastatin supplementation should be confirmed in a larger clinical trial.
PMID: 32926874 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Lefkou E, Varoudi K, Pombo J, Jurisic A, Jurisic Z, Contento G, Girardi G Tags: Biochem Pharmacol Source Type: research
More News: Antiphospholipid Syndrome | Aspirin | Clinical Trials | Drugs & Pharmacology | Hughes Syndrome | OBGYN | Perfusion | Perinatology & Neonatology | Pravastatin | Pregnancy | Statin Therapy | Study | Women